In my view, having patent policies does not mean more innovation. We currently have an institutionalized corporate welfare system. So what I am trying to show is that patent policies are not necessarily the best tool to improve therapeutic innovation.
In terms of policies, we can set up patents and other innovation policies. There is something simple right now that England or the United Kingdom is trying out. It is called value-based pricing, meaning that you agree to pay for a drug based on its therapeutic innovation. So you will pay for innovation, for the results on health, not for the commercialized product.
In my view, that would be a great way to encourage innovation. You bring us innovation, we will pay for it; you bring us something insignificant, we are not going to pay for that.